Across the recent three months, 8 analysts have shared their insights on Novo Nordisk NVO, expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 7 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $160.38, a high estimate of $163.00, and a low estimate of $160.00. Observing a 1.99% increase, the current average has risen from the previous average price target of $157.25.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Novo Nordisk among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $160.00 | $160.00 |
| Evan David Seigerman | BMO Capital | Lowers | Outperform | $160.00 | $170.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $160.00 | $160.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $160.00 | $160.00 |
| Evan David Seigerman | BMO Capital | Maintains | Outperform | $163.00 | $163.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $160.00 | $160.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $160.00 | $160.00 |
| John Eade | Argus Research | Raises | Buy | $160.00 | $125.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Novo Nordisk. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Novo Nordisk compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Novo Nordisk's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Novo Nordisk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Novo Nordisk analyst ratings.
Get to Know Novo Nordisk Better
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk: A Financial Overview
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Novo Nordisk's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.34% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 29.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 18.97%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Novo Nordisk's ROA stands out, surpassing industry averages. With an impressive ROA of 6.0%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Novo Nordisk adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
